Scotto, Nana
F. Hoffmann-La Roche AG
2 papers on CoChat
Most cited papers
- Verified
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 230
- Verified
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 177
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free